Trophic serves as a strategic partner for all aspects of communications for life science companies. We apply a deep understanding of both the science and business of drug development and the capital needed for success. Based on breadth and depth of experience, Trophic has become the go-to advisory for presenting corporate stories and scientific concepts. Current client portfolio ranges from biotech start-ups, listed biopharmas and small and large pharmaceutical companies.


Follow us on Twitter to stay tuned on biotech news and the inner workings of the Trophic team

This week @HerantisPharma announced Phase 1-2 topline results from the #ClinicalTrial testing its proprietary neuroprotective factor & novel drug candidate, CDNF in #ParkinsonsDisease patients. See here for the full announcement:

Herantis is hosting a #Webcast at 10:00 AM CET today to discuss the Phase 1-2 CDNF #ClinicalTrial results. To listen in, please register here: #ParkinsonsDisease

Another year, another scone! #HappyBirthday to our wonderful Vice President, @StephAmaSing! In true Trophic tradition, we had a great time celebrating over a tasty Italian lunch followed by homemade baked goods. Of course, we were not the only ones eyeing the treats… #AllesGute!

Load More...